HS
Therapeutic Areas
Vicore Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Buloxibutid (C21) | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2b |
Leadership Team at Vicore Pharma
AM
Ahmed Mousa
Chief Executive Officer
HJ
Hans Jeppsson
Chief Financial Officer
JR
Johan Raud
Chief Scientific Officer
BV
Bernt van den Blink
Chief Medical Officer
MN
Mikael Nygård
Chief Operating Officer
HB
Helen Barker
Chief Technology Officer
JH
Jimmie Hofman
Chief Business Officer
JG
Jacob Gunterberg
Board Member
HH
Heidi Hunter
Board Member
EB
Elisabeth Björk
Board Member